Will The New HPV Vaccine Prove A Shot In The Arm For Merck?

Merck & Co. Inc. (MRK: Quote) has received approval from FDA for Gardasil 9, a new vaccine that provides broader protection than previously approved Gardasil against HPV-related cancers.

Formerly known as V503, Gardasil 9 is approved for use in females ages 9 through 26 and males ages 9 through 15 for the prevention of cervical, vulvar, vaginal and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58, and for the prevention of genital warts caused by HPV types 6 or 11.